China genomics giant BGI targets A-share IPO

BGI, one of the world’s largest genome sequencing firms, plans to list in China to help fund growth and acquisitions but it is unclear if the IPO will see light in 2016.

China genomics giant BGI targets A-share IPO

BGI, one of the world’s largest genome sequencing companies, is targeting an A-share Chinese listing to help raise capital for development and acquisitions, some of them overseas.

However, it is unclear when the eye-catching initial public offering will see light.

The company, which previously abandoned plans to list in Hong Kong, aims to launch the IPO by the end of the year, Mao Mao, BGI's newly appointed chief science officer,...

To continue reading, please login or register for free

Click for more on: china | ipo | csrc | bgi | health | citic securities | ubs | sequoia

Print Edition

FinanceAsia Print Edition

CONFERENCES